Cancer Treatment Reviews
Volume 36, Issue 2 , Pages 164-176, April 2010

An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome

  • Tariq I. Mughal

      Affiliations

    • Department of Haematology, Guy’s & St Thomas’s NHS Hospital, London SE1 9RT, UK
    • Corresponding Author InformationCorresponding author. Tel.: +1 901 497 1185.
  • ,
  • A. Ahsan Ejaz

      Affiliations

    • Division of Nephrology, Hypertension and Transplantation, University of Florida, P.O. Box 100224, Gainesville, FL 32610, USA
    • Tel.: +1 352 265 0139; fax: +1 352 392 3581.
  • ,
  • John R. Foringer

      Affiliations

    • The Division of Renal Diseases and Hypertension, Section of Critical Care Nephrology, The University of Texas, Medical School at Houston, M.D. Anderson Cancer Center, Houston, TX 77030, USA
    • Tel.: +1 713 500 6868; fax: +1 713 500 6882.
  • ,
  • Bertrand Coiffier

      Affiliations

    • Department of Hematology, Hospices Civils de Lyon, Lyon, France
    • Tel.: +33 04 78 86 11 93; fax: +33 04 78 86 65 68.

Received 8 September 2009; received in revised form 29 October 2009; accepted 3 November 2009. published online 25 December 2009.

Summary 

Tumor lysis syndrome (TLS) is a potentially life-threatening metabolic disorder that occurs when tumor cells undergo rapid decomposition spontaneously or in response to cytoreductive therapy. Delayed recognition of the metabolic imbalances caused by the massive release of tumor cell contents may result in clinical complications such as acute kidney injury, seizures, and cardiac arrhythmias. Prevention, the key principle in TLS management, relies on the identification of patients at risk for developing TLS during chemotherapy or because of disease progression. TLS-related risk factors pertain to tumor type (particularly hematologic malignancies), specific tumor characteristics (e.g. bulky tumor, high cellular proliferation rate, sensitivity to cytoreductive therapy), and other host-related factors. A comprehensive grading system proposed by Cairo and Bishop classifies TLS syndromes into laboratory or clinical TLS, thus facilitating TLS prevention and management. The mainstays of TLS management include monitoring of electrolyte abnormalities, vigorous hydration, prophylactic antihyperuricemic therapy with allopurinol, and rasburicase treatment of patients at high TLS risk or with established hyperuricemia. Urine alkalinization and use of diuretics remain controversial clinical practices. In this review, we describe the incidence of, risk factors for, and diagnostic characteristics of TLS and summarize strategies for the prevention and management of TLS-associated metabolic abnormalities, particularly hyperuricemia. We specifically highlight recently published TLS management guidelines, which focus on the prevention of TLS and hyperuricemia based on a patient’s level of risk, and the important role of nephrologists in the prevention and treatment of one of the most serious complications of TLS, acute kidney injury.

Keywords: Tumor lysis syndrome, TLS, Rasburicase, Hyperuricemia, Uric acid, Acute kidney injury

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0305-7372(09)00162-5

doi:10.1016/j.ctrv.2009.11.001

Refers to erratum:

  • Erratum to “An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome” [Cancer Treatment Rev. 36 (2010) 164–176] , 10 May 2010

    Tariq I. Mughal, A. Ahsan Ejaz, John R. Foringer, Bertrand Coiffier
    Cancer Treatment Reviews August 2010 (Vol. 36, Issue 5, Page 442)

Cancer Treatment Reviews
Volume 36, Issue 2 , Pages 164-176, April 2010